MSc Statistics, Hematology, Oncology and genetic research center of Shahid Sadoughi University of Medical Sciences and Health Services. Yazd, Iran.

A frequent side effect of chemotherapy for cancer patients is fever and neutropenia. Hospitalization and empiric antibiotic medication are typically used to treat it. Due to their toxicity to joints and cartilage, fluoroquinolone use is restricted. In this study, the effectiveness of oral ciprofloxacin and intravenous ceftazidim were compared in patients with low risk febrile neutropenic lymphocytic leukaemia.

72 patients under the age of 14 who experienced 92 episodes of febrile neutropenia were prospectively observed for two years. G-CSF was administered to all patients along with amikacin 15 mg/kg/d and intravenous ceftazidim 100 mg/kg/d over a 24-hour period. These episodes were divided into two groups at random. For at least three days, Group A received IV ceftazidime and amikacin. They received oral cefixim 8 mg/kg daily after discharge. After being released, Group B got seven days of oral ciprofloxacin (20 mg/kg/day). Failure was defined as a temperature of 38 °C or greater for more than 72 hours.

Failure of oral ciprofloxacin for 7 days following 24 hours of intravenous ceftazidim plus amikasin was 4.3%, but failure of intravenous ceftazidim plus amikasin for at least 4 days in the hospital was 6.5% in low risk febrile neutropenic children. Patients who got ciprofloxacin experienced no arthrtoxicity.

Children with leukaemia and low risk FN can receive safe and effective empirical therapy with oral ciprofloxacin.

Keywords: Acute Lymphocytic Leukemia, Neutropenia, and Ciprofloxacin

Febrile neutropenia is a typical entanglement of disease chemotherapy. It is effortlessly overseen by hospitalization and empiric organization of parenteral anti-microbials (1). This administration plainly has demonstrated to lessen contamination horribleness and mortality and has been viewed as the norm of care. In any case, ongoing reports and a past randomized preliminary proposed that an okay subset of kids with febrile neutropenia under chemotherapy could benefit of an oral anti-microbial short term approach (2). Throughout the course of recent many years, extensive changes have happened in the kinds of microscopic organisms causing contaminations in febrile patients with neutropenia and disease. They incorporate a significantly lower frequency of gram-negative diseases, for example, Pseudomonas aeruginosa, and an increment pace of gram-positive contaminations, predominantly staphylococcus epidermidis and different types of streptococci (3). Mortality of the gram-positive coccal bacteremia in neutropenic patients is moderately low. Gram-negative bacteremic episodes are related with higher death rates, which actually address 30% of all bacteremias (4). In the beyond quite a while, a blend of ceftazidime in addition to amikacin has been laid out as a standard routine in febrile neutropenia (5,6). A few examinations have utilized various regimens, either as monotherapy or as consolidated treatment, which have been led to track down the best routine (7-10). Ceftazidim is a third-age cephalosporin with a wide range of activity that is not difficult to utilize. Ciprofloxacin is a manufactured 4-quinolone bactericidal anti-infection against a wide scope of gram-positive and gram-negative creatures, including P. aeruginosa, that has a low pace of nephrotoxicity (11).The fluoroquinolones are a significant gathering of anti-infection agents broadly utilized in the treatment of different contaminations illness in grown-ups because of a brilliant range of movement, great tissue entrance and helpful methods of organization. Their utilization in youngsters is restricted because of conceivable fluoroquinolone-actuated joint ligament harmfulness noticed for the most part in adolescent creature researchs (12).

Except for cystic fibrosis and life jeopardizing contaminations, the utilization of fluoroquinolones in pedietric ought to be restricted to gram-negative neonatal meningitis, salmonella, and shigella, diseases, ongoing suppurative otitis media and a few instances of muddled intense otitis media. (12) Untalented purposes of flouroquinolones in youngsters especially in local area procured lower respiratory contamination could speed up the rise of pneumococal opposition (12). Choice of patient with okay febrile neutropenia is significant for the best administration. Okay patients characterized as quiet with early indications of bone marrow recuperation, brief span of fever, nonappearance of comorbidity factors, and a prescient time of neutropenia of under 10 days (2). A few randomized controlled preliminaries have tended to the utilization of haematopoietic development factors in febrile neutropenic patients (13). These examinations show that granulocyte state animating component (GCSF) utilized in febrile neutropenic patients, reliably abbreviates the length of neutropenia, yet doesn't predictably prompt goal of disease or more limited time in clinic (14). This study meant to think about oral ciprofloxacin in early medical clinic release patients with intravenous ceftazidim and amikacin for generally safe febrile neutropenia.

From March 2008 to June 2009, this prospective, randomised, controlled trial was carried out. This study's objective was to assess the effectiveness and safety of giving febrile neutropenic children intravenous ceftazidim plus amikacin for 24 hours, followed by oral ciprofloxacin. after chemotherapy with ALL. 92 episodes of okay febrile neutropenia in 72 youngsters (mean age: 7.185 years; range: 0-14 years) were remembered for randomized controlled single establishment preliminary. The incorporation standards was age under 14 years of age, fever (equivalent or in excess of 38 °C), cut off neutropenia (outright neutrophil count under 500/mm3), negative blood culture, great clinical condition, control of nearby contamination, reduction, and guardians' collaboration. The rejection standards included hemodynamic shakiness, serious comorbidity, parchedness, cut off mucositis, pneumonia, and bone marrow transplantation (2). Fringe blood and pee societies and chest X-beam were performed for all patients before treatment. Blood tests from port catheters and fringe veins for quantitative differential societies were taken. Skin and delicate tissue diseases, the runs, pharyngitis, or any thought contamination were carry out utilizing bacterial societies. Every one of the patients got intravenous ceftazidim 100 mg/kg in addition to amikacin 15 mg/kg day to day, for 24 hours. Then, at that point, they arbitrarily distributed to two 46 episodes. Bunch A got IV ceftazidim and amikacin for something like three days and released with oral cefixim (8 mg/kg/day) for 4 days. Patients in bunch B were released and gotten oral ciprofloxacin (20 mg/kg/day) for seven days. Each of the patients got GCSF. Disappointment was characterized, as temperature higher than 38 °C for over 72 hours after anti-microbial treatment.

Effective treatment was characterized no fever and no re-confirmation because of another fever contamination occasion in no less than 7 days of release or another febrile episode during a similar episode of neutropenia. Results were analyzed by the Fisher precise test or Chi square test. P esteem not exactly or equivalent to 0.05 was expected to be as critical.

Fever and neutropenia are still potential fatal side effects of chemotherapy for cancer (7). Prior to recently, all febrile neutropenic patients required hospitalisation in order to receive empiric, intravenous, broad-spectrum antibiotic therapy (2). For low risk patients, it is possible to provide less intensive care and a more convenient course of treatment (15). The effectiveness of the new programme was greatly influenced by the careful selection of the lower risk patients.regimens. Different examinations have utilized comparable rules, avowing their prescient worth in the setting of fever and neutropenia (16,17 and 2). This study shows that febrile neutropenic youngsters with okay rules may be securely and successfully oversaw utilizing everyday intravenous ceftazidim in addition to amikacin followed by oral ciprofloxacin for 7 extra days. In consistent patients, with lower risk standards, the treatment could be changed following 1 day of intravenous treatment to an oral anti-toxin, for example, cefixime, ciprofloxacin, ofloxacin, clindamycin, or quinolone related with amoxicillin/clavulanic corrosive. The patients could be released before from the clinic, with cautious development (2,18) Amikacin could cause nephrotoxicity. Subsequently, mix of high, when everyday portion of ceftriaxon with ciprofloxacin, a manufactured 4-quinolone anti-microbial, are utilized. This bactericidal routine is against a wide scope of gram-positive and gram-negative life forms including P. aeruginosa, which has a low pace of nephrotoxicity (11).

In a review directed by the EORTC (European Association for Exploration and Therapy of Malignant growth), the frequency of nephrotoxicity in bunches getting a solitary day to day portion of amikacin was somewhere in the range of 1.2% and 3.0%, while the rate of ototoxicity was 9% in the amikacin bunch getting a solitary day to day portion contrasted with 7% in the amikacin bunch getting it like clockwork (19). The utilization of fluoroquinolons in kids ought to be particular and directed all the more cautiously. These medications are at present utilized in pediatrics as second-line anti-infection agents, for the most part in cases in which any remaining past treatment have fizzled. Except for cystic fibrosis and hazardous diseases, their utilization as first line treatment ought to be restricted to gram-negative neonatal meningitis, salmonella, and shigella spp. contaminations, constant suppurative otitis media and a few instances of muddled intense otitis media non-receptive to beginning therapy. The majority of the distributed examinations neglected to identify an expanded pace of articular unfavorable impacts in youngsters treated with fluoroquinolons (12). In this study cut off entanglement was not seen yet minor difficulty, for example, gentle queasiness and cerebral pain were noticed.

1- Mullen CA,Petropoulos D,Roberts WM,Rytting M,Zipf T,Chan KW,et al. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer, 1999; 86(1):126-34.

2-. Paganini H, Rodriguez-Brieshcke T, Zubizarreta P, Latella A, Firpo V, Casimir L, et al. Oral ciprofloxacin in the management of children with cancer with lower risk febrile neutropenia. 2001; 91(8):1563-7.

3-Zinner SH. Changing epidemiology of infections in patients with neutropenia and cancer Clin Infect Dis. 1999; 29:490–4.

4- Feld R. Vancomycin as part of initial empirical antibiotic therapy for febrile neutropenia in patients with cancer: pros and cons. Clin Infect Dis. 1999;29:503–7.

5- Nucci M, Pulcheri WA, Spector N, de Oliveira HP. Ceftazidime and amikacin as empirical treatment of febrile episodes in neutropenic patients. J Infect. 1994; 28:335–6.

6- Santhosh-Kumar CR, Ajarim DS, Harakati MS, al Momen AK, al Mohareb F, Zeitany RG. Ceftazidime and amikacin as empiric treatment of febrile episodes in neutropenic patients in Saudi Arabia. J Infect 1992;25:11–9.

7- De Pauw BE, Deresinski SC, Feld R, Lane-Allman EF, Donnelly JP. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. Ann Intern Med. 1994; 120:834–44.

8- Bodey GP, Rolston KV, Raad II. Ciprofloxacin versus tobramycin for neutropenic fevers. Ann Intern Med 2003; 138:435:436.

9- Pérez C, Sirham M, Labarca J, Grebe G, Lira P, Oliva J, et al. Imipenem/cilastatin versus ceftazidimeamikacin in the treatment of febrile neutropenic patients. Rev Med Chil 1995; 123(3):312–20.

10- Hazel DL, Graham J, Dickinson JP, Newland AC, Kelsey SM.Piperacillin-tazobactam as empiric monotherapy in febrile neutropenic patients with haematological malignancies. J Chemother 1997; 9: 267–72.

11- Metallidis S, Kollaras AP, Giannakakis P, Seitanidis B, Kordosis K, Nikolaidis K, et al. A prospective,controlled, randomized, non-blind, comparative study of the efficacy and safety of a once daily high dose of ceftriaxone plus ciprofloxacin versus thrice daily ceftazidime plus amikacin in empirical therapy for febrile neutropenic patients,European Journal of Internal Medicine 2008;19: 619–624.

12-Leibovitz E. The use of fluoroquinolones in children.Current Opinion in Pediatrics February, 2006 :64-70.

13-Ozer H, Armitage JO, Bennett CL, et al. 2000 update of recommendations for the use of heamatopoietic colonystimulating factors. J Clin Oncol 2000; 18:3558–85.

14-Sheila M. Lane, Janice A. Kohler, The management of febrile neutropenia, Current Paediatrics. 2005;15:400–405.

15- Innes HE, Smith DB, O'Reilly SM, Clark PI, Kelly V, Marshall E. Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer. Br J Cancer. 2003; 89(1):43-9.

16-Kern WV, Cometta A, de Bock R, Langenaeken J, Paesmans M, Gaya H, et al. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. N Engl J Med 1999; 341:312–8.

17. Mullen CA, Petropoulos D, Roberts M, Rytting M, Zipf T, Chan KW, et al. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer 1999; 86: 126–34.

18- Freifeld A, Marchigiani D, Walsh T, Chanock S, Lewis L, Hiemenz J, et al . A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 1999; 341(5):305-1.

19- Calandra T. Efficacy and toxicity of single-daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 1993: 584–93.

Zare A .When treating acute lymphoblastic leukaemia patients with low risk febrile neutropenia, oral ciprofloxacin is superior than intravenous ceftazidim. World Journal Of Hematology And Oncology 2022.